Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Darts portfolio
ALNYLAM PHARM ? +134.93 +5.43 +4.1931 +129.5000 USD ORD
SPECTRUM PHARMS ? +18.62 -0.38 -2.0000 +19.0000 USD ORD
CYTOKINETICS INC ? +12.50 +0.30 +2.4590 +12.2000 USD ORD
EXELIXIS INC ? +26.50 -0.09 -0.3385 +26.590000 USD ORD
RESVERLOGIX/d ? +1.30 -0.01 -0.76 +1.31 CAD ORD
PEREGRINE PHARMA ? +4.45 +0.03 +0.6787 +4.4200 USD ORD
IBIO INC/d ? +0.290700 -0.006700 -2.2529 +0.297400 USD ORD
VERICEL CORP ORD ? +3.955200 -0.269800 -6.3858 +4.225000 USD ORD
TAPIMMUNE INC ? +2.891900 -0.031400 -1.0741 +2.923300 USD ORD
VERASTEM INC ? +3.36 -0.01 -0.2967 +3.3700 USD ORD
XOMA CORPORATION ? +27.76 +0.17 +0.6162 +27.5900 USD ORD
CYCLACEL PHA ORD ? +1.605000 +0.005000 +0.3125 +1.6000 USD ORD
BIONDVX PHRMCTCL ? +6.655900 -0.134100 -1.9750 +6.7900 USD DRC
SYNLOGIC INC ORD ? +13.58 +0.14 +1.0417 +13.4400 USD ORD
Context-dependent compensation among phosphatidylserine-recognition receptors
Published online:07 November 2017
Why Do Immune Checkpoint Inhibitors Work for Only Some People with Cancer?
https://www.mskcc.org/blog/why-do-immune-checkpoint-inhibitors-only-work-some-people
CP for you
Les derniers essais cliniques dans le monde sur les tumeurs de cerveau 2015-2017
https://glioblastome.fr/maladie/essais.html
P3.02c-051 A Pre-Treatment Serum Test Based on Complement and IL-10 Pathways Identifies Patients Benefiting from the Addition of Bavituximab to Docetaxel
Topic: IT
David Gerber
Joanna Roder
Nikoletta Kallinteris
Leora Horn
Gyorgy Losonczy
Ronald Natale
Min Tang
Heinrich Roder
Joseph Shan
Rachel Sanborn
If known pls delete
http://www.jto.org/article/S1556-0864(16)33087-8/fulltext
PS-Targeting - that´s why I´m long PPHS.
Miles for Mary research fundraiser to be held Nov. 6
No no stay and stay cool.
CAR T-CELL THERAPY FOR MULTIPLE MYELOMA - A PIPELINE ANALYSIS REPORT 2017 - RESEARCH AND MARKETS
BSW
11/03/2017 4:07 PM
CAR T-cell Therapy for Multiple Myeloma - A Pipeline Analysis Report 2017 - Research and Markets
The "CAR T-cell Therapy for Multiple Myeloma - A Pipeline Analysis Report" (https://www.researchandmarkets.com/research/rpkgs6/car_tcell) report has been added to Research and Markets' offering.
Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma: An insight
CAR T-cell Therapy for Multiple Myeloma - A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.
The CAR T-cell therapy for multiple myeloma pipeline analysis report includes ongoing clinical and non-clinical trends in the global CAR T-cell therapy for multiple myeloma.
Most of the pipeline therapeutics are in early stages of development; there is no CAR T-cell therapy approved to date for multiple myeloma treatment, but other treatments are available. A long-lasting and less-frequent dose can impact the overall multiple myeloma market.
In recent past, many pilot studies and early clinical trials have shown very promising results in the treatment of multiple myeloma with CAR T-cell therapy. However, the market has yet to witness the approval of the first CAR T-cell therapy for multiple myeloma, and it may take a few years from now. The currently available treatment for multiple myeloma include chemotherapy and other drugs, bisphosphonates, radiation, surgery, stem cell transplant, and plasmapheresis.
According to the National Cancer Institute (NIH), in 2017, there will be 30,280 new cases of myeloma and an estimated 12,590 deaths occur due to this disease in the US.
Major companies
Juno Therapeutics
Kite Pharma
Novartis
Collectis
Key Topics Covered:
Part 01: Executive Summary
Part 02: Scope Of The Report
Part 03: Research Methodology
Part 04: Chimeric Antigen Receptor (Car) T-Cell Therapy For Multiple Myeloma: An Insight
Part 05: Major Regulatory Authorities
Part 06: Pipeline Landscape
Part 07: Comparative Analysis
Part 08: Indication Analysis
Part 09: Therapeutic Assessment By Therapy
Part 10: Therapeutic Assessment By Roa
Part 11: Therapeutic Assessment By Target
Part 12: Key Companies
Part 13: Appendix
For more information about this report visit https://www.researchandmarkets.com/research/rpkgs6/car_tcell (https://www.researchandmarkets.com/research/rpkgs6/car_tcell)
View source version on businesswire.com: http://www.businesswire.com/news/home/20171103005591/en/ (http://www.businesswire.com/news/home/20171103005591/en/)
Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.com (mailto:press@researchandmarkets.com) For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900Related Topics: Genomics (https://www.researchandmarkets.com/categories.asp?cat_id=22&campaign_id=rpkgs6) , Oncology Drugs
(https://www.researchandmarkets.com/categories.asp?cat_id=122&campaign_id=rpkgs6) , Leukemia Drugs
(https://www.researchandmarkets.com/categories.asp?cat_id=209&campaign_id=rpkgs6)
Copyright Business Wire 2017
nBw5fQh9va
© Thomson Reuters 2017. All rights reserved.
Endosomal phosphatidylserine is critical for the YAP signalling pathway in proliferating cells
Published online:01 November 2017
https://www.nature.com/articles/s41467-017-01255-3
That would be the logical continuation after all those years
Procoagulant microparticles derived from cancer cells have determinant role in the hypercoagulable state associated with cancer.
Rousseau A1, Van Dreden P2, Khaterchi A3, Larsen AK1, Elalamy I1, Gerotziafas GT1.
Author information
Abstract
Hypercoagulablity is a common alteration of blood coagulation in cancer patients. However, the procoagulant activity of cancer cells is not sufficient to induce hypercoagulability. The present study was aimed to identify the mechanism with which hypercoagulabilty is produced in the presence of cancer cells. We focused on the analysis of the procoagulant elements carried by cancer cell-derived microparticles (CaCe-dMP) and we evaluated the impact of microparticles associated with the cancer cells from which they stem on thrombin generation. CaCe-dMP from the cancer cells were isolated from the conditioned medium and analyzed for tissue factor (TF) and procoagulant phospholipid expression. Thrombin generation of normal plasma was assessed by the Thrombinoscope (CAT®) in the presence or absence of pancreas adeno-carcinoma cells (BXPC3) or breast cancer MCF7 cells supplemented with the respective CaCe-dMP. Both BXPC3 and MCF7 cells express abundant amounts of active TF. Phosphatidylserine was identified on the surface of CaCe-dMP, unlike the cancer cells themselves. The expression of TFa by the microparticles was significantly higher to that observed on the cancer cells. Culture of the cancer cells with their microparticles resulted in thrombin generation significantly higher as compared to the upper normal limit. In conclusion, cancer cells 'enrich' the microenvironment with procoagulant elements, especially procoagulant micro-particles which express TF and procoagulant phospholipids. The association of cancer cells with procoagulant microparticles is necessary for a state of hypercoagulability, at the level of the tumoral microenvironment. The intensity of the hypercoagulability depends on the histological type of the cancer cells.
https://www.ncbi.nlm.nih.gov/pubmed/29075792
RONIN TRADING AND SW INVESTMENT MANAGEMENT RELEASE PRESENTATION HIGHLIGHTING CONCERNS WITH BOARD OF PEREGRINE PHARMACEUTICALS
PRN
10/30/2017 4:54 PM
Ronin Trading and SW Investment Management Release Presentation Highlighting Concerns with Board of Peregrine PharmaceuticalsRonin Believes Recent Changes are Insufficient and Calls on Peregrine to Justify Long-Standing Incumbent Directors' Continued Service on the BoardRonin Reiterates Demand for Peregrine to Hold 2017 Annual Meeting Immediately to Enable Stockholders to Elect Representatives of their Choosing PR Newswire
CHICAGO, Oct. 30, 2017
CHICAGO, Oct. 30, 2017 /PRNewswire/ -- Ronin Trading, LLC and SW Investment Management LLC (together with the other participants in their solicitation, 'Ronin' or 'we'), collectively the largest stockholder of Peregrine Pharmaceuticals, Inc. ('Peregrine' or the 'Company') (NASDAQ:PPHM), with aggregate beneficial ownership of approximately 9.6% of the Company's outstanding shares of common stock, today issued an initial investor presentation explaining its continued concerns with the composition of the Company's Board of Directors (the 'Board').
In the presentation, Ronin explained its belief that, given the Company's abysmal performance under the leadership of long-standing incumbent directors Carlton M. Johnson Jr., Steven W. King, David H. Pohl and Eric S. Swartz, a complete overhaul of the boardroom is warranted. Specifically, Ronin does not believe there is a justifiable reason for the long-standing incumbents' continued service as directors and is convinced that the Board must be reconstituted with independent directors with relevant industry experience who were not hand-picked by the incumbents.
Ronin has nominated a slate of six highly qualified and independent director candidates – James J. Egan, Richard B. Hancock, Joel McComb, Gregory P. Sargen, Brian W. Scanlan and Saiid Zarrabian – and once again calls on the Board to call the 2017 annual meeting of stockholders immediately to enable the Company's stockholders to elect representatives of their choice.
Ronin's presentation is available on the SEC's website and can be viewed by clicking the following link: https://tinyurl.com/PPHM-presentation1.
CERTAIN INFORMATION CONCERNING THE PARTICIPANTS
Ronin Trading, LLC, together with the other participants named herein (collectively, 'Ronin'), has filed a preliminary proxy statement and an accompanying proxy card with the Securities and Exchange Commission ('SEC') to be used to solicit votes for the election of its slate of six highly qualified director nominees at the 2017 annual meeting of stockholders Peregrine Pharmaceuticals, Inc., a Delaware corporation (the 'Company').
RONIN STRONGLY ADVISES ALL STOCKHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT HTTP://WWW.SEC.GOV (HTTP://WWW.SEC.GOV). IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST.
The participants in the solicitation are Ronin Trading, LLC ('Ronin Trading'), John S. Stafford, III, SWIM Partners LP ('SWIM Partners'), SW Investment Management LLC ('SW Management'), Stephen White, Roger Farley, James J. Egan, Richard B. Hancock, Joel McComb, Gregory P. Sargen, Brian W. Scanlan and Saiid Zarrabian.
As of the date hereof, Ronin Trading directly beneficially owned 3,310,652 shares of the Company's common stock, $0.001 par value per share ('Common Stock'), including 137,260 shares of Common Stock that may be acquired upon the conversion of 115,299 shares of the Company's 10.50% Series E Convertible Preferred Stock, $0.001 par value per share ('Series E Preferred Stock'). Mr. Stafford, as the Manager of Ronin Trading, may be deemed to beneficially own the 3,310,652 shares of Common Stock beneficially owned directly by Ronin Trading. As of the date hereof, SWIM Partners directly beneficially owned 510,333 shares of Common Stock, including 10,333 shares of Common Stock that may be acquired upon the conversion of 8,680 shares of Series E Preferred Stock. As of the date hereof, an account separately managed by SW Management (the 'SW Account') held 203,714 shares of Common Stock, including 3,714 shares of Common Stock that may be acquired upon the conversion of 3,120 shares of Series E Preferred Stock. SW Management, as the general partner and investment adviser of SWIM Partners and the investment adviser of the SW Account, may be deemed to beneficially own the 714,047 shares of Common Stock beneficially owned in the aggregate by SWIM Partners and held in the SW Account. Mr. White, as the Manager of SW Management, may be deemed to beneficially own the 714,047 shares of Common Stock beneficially owned in the aggregate by SWIM Partners and held in the SW Account. As of the date hereof, Mr. Farley directly beneficially owned 301,190 shares of Common Stock, including 1,190 shares of Common Stock that may be acquired upon the conversion of 1,000 shares of Series E Preferred Stock. As of the date hereof, Messrs. Egan, Hancock, McComb, Sargen, Scanlan and Zarrabian did not beneficially own any securities of the Company.
Investor Contact:
Stephen White
SW Investment Management LLC
(312) 765-7033
View original
content:http://www.prnewswire.com/news-releases/ronin-trading-and-sw-investment-management-release-presentation-highlighting-concerns-with-board-of-peregrine-pharmaceuticals-300545548.html
SOURCE Ronin Trading, LLC and SW Investment Management LLC
Copyright (c) 2017 PR Newswire Association,LLC. All Rights Reserved.
nPnbPcvg9a
© Thomson Reuters 2017. All rights reserved.
Phosphatidylserine-Induced Conformational Modulation of Immune Cell Exhaustion-Associated Receptor TIM3
Published online:19 October 2017
https://www.nature.com/articles/s41598-017-14064-x#Bib1
Never ever ! Imo
You have my vote!
Ronin Trading And SW Investment Management Announce Additional Nominations To Board Of Peregrine Pharmaceuticals - PRN
27-Oct-2017 14:30
Ronin Trading And SW Investment Management Announce Additional Nominations To Board Of Peregrine PharmaceuticalsCDMO Executive Richard (Rick) B. Hancock and Life Sciences Executive Joel McComb Join Slate of Six Highly Qualified Candidates for Election at Upcoming 2017 Annual MeetingRonin Reiterates Demand for Peregrine to Hold 2017 Annual Meeting without Further Delay PR Newswire
CHICAGO, Oct. 27, 2017
CHICAGO, Oct. 27, 2017 /PRNewswire/ -- Ronin Trading, LLC and SW Investment Management LLC (together with the other participants in their solicitation, "Ronin" or "we"), collectively the largest stockholder of Peregrine Pharmaceuticals, Inc. ("Peregrine" or the "Company") (NASDAQ: PPHM), with aggregate beneficial ownership of approximately 9.6% of the Company's outstanding shares of common stock, today issued the following statement with respect to Peregrine.
We are glad to announce our additional nominations of Richard (Rick) B. Hancock, a +30-year biologic contract design and manufacturing organization ("CDMO") veteran, and Joel McComb, an entrepreneur and +25-year veteran of life sciences companies, for election to Peregrine's Board of Directors (the "Board") at the Company's 2017 annual meeting of stockholders (the "2017 Annual Meeting"). We believe Mr. Hancock's prior experience as the President and CEO of Althea Technologies, Inc. ("Althea"), a large molecule CDMO that was acquired by Ajinomoto Co., Inc. in 2013 for $175 million, as well as his years of cGMP manufacturing experience prior to Althea, make him well qualified for the Board. We believe Mr. McComb's decades of experience in senior roles at major life sciences companies and deep understanding of the processes and equipment used for analysis and production during biologic drug discovery will make him a valuable addition to the Board. Messrs. Hancock and McComb's impressive qualifications, which are discussed in greater detail below, make them great additions to our previously announced slate of nominees – James J. Egan, Gregory P. Sargen, Brian W. Scanlan and Saiid Zarrabian.
We remain confident that stockholders are eager for a wholesale change to the composition of the Board and executive leadership regardless of the Company's eleventh-hour actions. It is apparent to us that the long-standing incumbent non-employee directors, Carlton M. Johnson Jr., David H. Pohl and Eric S. Swartz, continue to place their interests ahead of the Company and its stockholders, most recently by disclosing an amended non-employee director compensation program that pays a much smaller cash retainer; yet, it is not applicable to Messrs. Johnson, Pohl and Swartz as they are expected to "transition to the new non-employee director compensation program over a period of time,"(1) whatever that means. We reiterate our demand for the Company to promptly hold the 2017 Annual Meeting so stockholders have the opportunity to elect representatives capable of representing stockholders' best interests. With the Company having its slate of directors in place, what excuse is left now for failing to call the 2017 Annual Meeting?
Richard (Rick) B. Hancock has worked in the biologic CDMO industry for over 30 years in various operational and executive roles, serving most recently as President and CEO of Althea, a large molecule CDMO producing a wide range of biologics, vaccines and parenteral products. Mr. Hancock was Althea's CEO at the time it was purchased in 2013 for $175 million by multi-billion dollar Japanese chemicals company Ajinomoto Co., Inc. Prior to joining Althea in 1998, he was the Sr. Director of Operations at The Immune Response Corporation where he was responsible for manufacturing, process development, QA and related functions. He began his biotech career at Hybritech Inc. (now part of Eli Lilly & Company), one of the earliest pioneers in monoclonal antibodies where he was responsible for manufacturing and process development of injectable products. Mr. Hancock has made numerous technical presentations to industry organizations and published extensively on topics ranging from regulatory affairs and process and facility validation, to managing contract manufacturing relationships. He is currently the Chairman of the Board and Executive Director of Argonaut Manufacturing Services, Inc., a CDMO focused on the biotechnology and life sciences industries, and a director of each of Tempo Therapeutics, Inc., a company focused on regenerative tissue therapies using synthetic materials, and ALMA Life Sciences Foundation, a non-profit dedicated to bringing effective and inexpensive vaccines to those in need. Mr. Hancock received a BA in microbiology from Miami University.
Joel McComb is the CEO, Chairman and Co-Founder of BioSpyder Technologies, Inc., an innovative life sciences company that develops molecular profiling assay technology. From 2008-2010, Mr. McComb was a Senior Vice President and General Manager of Illumina, Inc., a $30 billion developer of genetic analytic tools for use with sequencing, genotyping and gene expression. From 2004-2007, Mr. McComb was the President of GE Healthcare's Life Sciences and Discovery Systems division with over $600 million in annual sales, and from 2007-2008 he was the President of GE Healthcare's $700 million Interventional Medicine division. Prior to GE Healthcare, Mr. McComb was the President, CEO and a director of Innovadyne Technologies, Inc., a fluidics technology company for drug discovery that was acquired in 2004 by Gilson, Inc., a private life sciences systems and equipment manufacturer. From 1995-2001 Mr. McComb held various positions at Beckman Coulter, Inc., including roles as General Manager of the Primary Care Diagnostic Division and Director of Corporate Business Development, Diagnostics and Bioresearch. Mr. McComb began his career in the Biotechnical Services Division of Charles River Laboratories (at the time a division of Bausch & Lomb Inc.) where he was a National Business Manager for the company's monoclonal antibody CDMO division. Mr. McComb previously was a director of Bio-Rad Laboratories, Inc., a $6.5 billion clinical diagnostics and instrumentation company, from July 2014 to April 2017, with its stock appreciating approximately 23.9% annualized during his tenure. Mr. McComb earned a Bachelor of Science degree in genetics from the University of California, Davis and an MBA from Golden Gate University.
CERTAIN INFORMATION CONCERNING THE PARTICIPANTS
Ronin Trading, LLC, together with the other participants named herein (collectively, "Ronin"), has filed a preliminary proxy statement and an accompanying proxy card with the Securities and Exchange Commission ("SEC") to be used to solicit votes for the election of its slate of six highly qualified director nominees at the 2017 annual meeting of stockholders Peregrine Pharmaceuticals, Inc., a Delaware corporation (the "Company").
RONIN STRONGLY ADVISES ALL STOCKHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT HTTP://WWW.SEC.GOV (HTTP://WWW.SEC.GOV). IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST.
The participants in the solicitation are Ronin Trading, LLC ("Ronin Trading"), John S. Stafford, III, SWIM Partners LP ("SWIM Partners"), SW Investment Management LLC ("SW Management"), Stephen White, Roger Farley, James J. Egan, Richard B. Hancock, Joel McComb, Gregory P. Sargen, Brian W. Scanlan and Saiid Zarrabian.
As of the date hereof, Ronin Trading directly beneficially owned 3,310,652 shares of the Company's common stock, $0.001 par value per share ("Common Stock"), including 137,260 shares of Common Stock that may be acquired upon the conversion of 115,299 shares of the Company's 10.50% Series E Convertible Preferred Stock, $0.001 par value per share ("Series E Preferred Stock"). Mr. Stafford, as the Manager of Ronin Trading, may be deemed to beneficially own the 3,310,652 shares of Common Stock beneficially owned directly by Ronin Trading. As of the date hereof, SWIM Partners directly beneficially owned 510,333 shares of Common Stock, including 10,333 shares of Common Stock that may be acquired upon the conversion of 8,680 shares of Series E Preferred Stock. As of the date hereof, an account separately managed by SW Management (the "SW Account") held 203,714 shares of Common Stock, including 3,714 shares of Common Stock that may be acquired upon the conversion of 3,120 shares of Series E Preferred Stock. SW Management, as the general partner and investment adviser of SWIM Partners and the investment adviser of the SW Account, may be deemed to beneficially own the 714,047 shares of Common Stock beneficially owned in the aggregate by SWIM Partners and held in the SW Account. Mr. White, as the Manager of SW Management, may be deemed to beneficially own the 714,047 shares of Common Stock beneficially owned in the aggregate by SWIM Partners and held in the SW Account. As of the date hereof, Mr. Farley directly beneficially owned 301,190 shares of Common Stock, including 1,190 shares of Common Stock that may be acquired upon the conversion of 1,000 shares of Series E Preferred Stock. As of the date hereof, Messrs. Egan, Hancock, McComb, Sargen, Scanlan and Zarrabian did not beneficially own any securities of the Company.
(1) Peregrine Form 8-K filed on October 23, 2017.
Investor Contact:
Stephen White
SW Investment Management LLC
(312) 765-7033
View original
content:http://www.prnewswire.com/news-releases/ronin-trading-and-sw-investmen...
SOURCE Ronin Trading, LLC and SW Investment Management LLC
Copyright (c) 2017 PR Newswire Association,LLC. All Rights Reserved.
Chemoradiation Combined with Phosphatidylserine-Targeting Antibody Enhances Systemic Anti-tumor Immune Responses
W. Jiang
,
Y. Wang
,
B. Freimark
,
L. Stepp
,
J. Shan
,
R.U. Komaki
,
S.H. Lin
DOI: http://dx.doi.org/10.1016/j.ijrobp.2017.06.297
Article Infoclick to expand contents
Recent advances in cancer immunotherapy have sparked significant interest in harnessing the body’s immune system to fight cancer. However, the response rates of cancer immunotherapies, including immune checkpoint blockade, remain low. Strategies to enhance anti-tumor immune responses by targeting different steps along the immune activation cascade that can complement T cell-based immunotherapies are clearly needed. Here, we examine whether the addition of an antibody that targets extracellular phosphatidylserine (PS), a molecule that is recognized by myeloid derived cells, can enhance anti-tumor immune responses of chemoradiation for non-small cell lung cancer (NSCLC). Chemoradiation (CRT) was combined with a murine monoclonal antibody (mch1N11). PS is highly expressed in both orthotopically and ectopically implanted 393P murine NSCLC models. Radiation dose was 2 Gy/day, given for 5 days. Chemotherapy consists of carboplatin and paclitaxel at a dose of 30 mg/kg and 10 mg/kg, respectively. PS-targeting antibody (mch1N11) was given at 3mg/kg for 2 weekly doses. For ectopic tumor models, bilateral tumors were established in the legs. Radiation was directed to the R leg and tumor on the L side was shielded. Tumor growth was measured either with CT imaging or digital caliper. Tumor infiltrating immune cell profiles were analyzed using immunohistochemistry. Survival analyses were performed using Kaplan-Meier method and compared using Log-rank test. CRT + mch1N11 treatment significantly inhibited growth and improved survival in mice implanted with orthotopic 393P tumors as compared to CRT alone (median: 21 vs. 15 days, HR: 2.77, P = 0.006). Tissue analyses showed that CRT significantly increased the expression of PD-L1 within the tumor and drastically reduced the number of tumor infiltrating CD8 T cells. For the CRT + mch1N11 group, a similar up-regulation of PD-L1 expression was noted. However, the addition of mch1N11 re-populated the infiltrating CD8 T cells within the tumor. In the bilateral tumor model, the addition of mch1N11 antibody to CRT resulted in tumor regression in ~40% of the non-irradiated tumors in the contralateral side as compared to 0% in the CRT alone or chemotherapy + mch1N11 groups. We showed that PS-targeting combined with standard CRT can significantly prolong survival in preclinical models of NSCLC and generate enhanced systemic anti-tumor immunity against lesions outside of the irradiated field. CRT up-regulated PD-L1 expression within the tumor and depleted tumor infiltrating cytotoxic CD8 T cells. The addition of mch1N11 antibody to CRT, however, was able to re-populate this critical immune effector cell population. Together, our results demonstrate that PS-targeting antibodies may be combined with CRT to enhance intrinsic tumor immunogenicity, activate systemic anti-tumor immune responses, and act as a priming strategy to sensitize the tumor to immune checkpoint inhibition with PD-1 or PD-L1 antibodies.
Author Disclosure: W. Jiang: None. Y. Wang: None. B. Freimark: Stock; Peregrine Pharmaceuticals. L. Stepp: Stock; Peregrine Pharmaceuticals, Inc.; American Cancer Society Regional Council, Baylor University School of Nursing. J. Shan: Stock; Peregrine Pharmaceuticals, Inc.; Peregrine Pharmaceuticals. R.U. Komaki: None. S.H. Lin: Research Grant; Elekta, Inc., Hitachi Chemical, Inc., Peregrine Pharmaceuticals, Inc., Roche/Genentech, STCube Pharmaceuticals, Inc.
View PDF
http://www.redjournal.org/article/S0360-3016(17)31349-4/abstract
Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy
http://www.tandfonline.com/doi/abs/10.1080/2162402X.2017.1385690
First-in-Man Evaluation of 124I-PGN650: A PET Tracer for Detecting phosphatidylserine as a Biomarker of the Solid Tumor Microenvironment
With Bavituximab. ... and PS....
If already posted pls delete.
Abstract
Purpose: PGN650 is a F(ab0
)2 antibody fragment that targets phosphatidylserine (PS), a marker normally absent that becomes
exposed on tumor cells and tumor vasculature in response to oxidative stress and increases in response to therapy. PGN650 was
labeled with 124I to create a positron emission tomography (PET) agent as an in vivo biomarker for tumor microenvironment and
response to therapy. In this phase 0 study, we evaluated the pharmacokinetics, safety, radiation dosimetry, and tumor targeting of
this tracer in a cohort of patients with cancer.
Methods: Eleven patients with known solid tumors received approximately 140 MBq (3.8 mCi) 124I-PGN650 intravenously and
underwent positron emission tomography–computed tomography (PET/CT) approximately 1 hour, 3 hours, and either 24 hours
or 48 hours later to establish tracer kinetics for the purpose of calculating radiation dosimetry (from integration of the organ
time-activity curves and OLINDA/EXM using the adult male and female models).
Results: Known tumor foci demonstrated mildly increased uptake, with the highest activity at the latest imaging time. There were
no unexpected adverse events. The liver was the organ receiving the highest radiation dose (0.77 mGy/MBq); the effective dose
was 0.41 mSv/MBq.
Conclusion: Although 124I-PGN650 is safe for human PET imaging, the tumor targeting with this agent in patients was less than
previously observed in animal studies.
https://www.google.at/url?sa=t&source=web&rct=j&url=http://journals.sagepub.com/doi/pdf/10.1177/1536012117733349&ved=0ahUKEwj22sbh8YnXAhWMvRoKHa3wAOY4FBAWCC0wBQ&usg=AOvVaw3DMkfx1Vw0MGApRT3iEPYl
Peregrine Pharmaceuticals Announces Appointment of Patrick Walsh to Board of Directors of Peregrine and Avid Bioservices - GNW
24-Oct-2017 14:05
TUSTIN, Calif., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company focused on helping improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Patrick Walsh as an independent member of the board of directors of both Peregrine and Avid Bioservices, the company’s wholly-owned contract development and manufacturing organization (CDMO) subsidiary. Mr. Walsh’s record of leading successful, high-growth CDMOs is well-documented in the industry and he has also led complex laboratory and pharmaceutical manufacturing operations including parenteral and active pharmaceutical ingredients (API) on a global scale.
“We are thrilled to add an individual with Patrick’s industry expertise and impressive track record of success to the Peregrine and Avid boards. The industry insight and knowledge that he has accumulated throughout his years of serving on the senior management teams of successful CDMOs, will prove invaluable as we continue to expand and enhance our CDMO business,” said Steven W. King, president and chief executive officer of Peregrine. “Since early September, we have made great progress in our stated goal of hiring a dedicated president focused on the CDMO business and expanding our board of directors with individuals with high quality CDMO industry experience. We believe that these key appointments strongly position our CDMO business to continue its growth and capture a more significant portion of the rapidly expanding business opportunities in this industry.”
Mr. Walsh currently serves as chief executive officer of Avista Pharma Solutions, a high-growth CDMO with over 220,000 square feet of facility space that provides pharmaceutical clients with a full suite of service offerings including analytical, microbiology, API, formulation, drug substance & drug product manufacturing expertise and capabilities. Prior to joining Avista Pharma, he was chief executive officer of AAIPharma Services, a private-equity backed CDMO at which he led a successful growth strategy culminating in the company’s sale for more than 4.5 times return on invested capital. Mr. Walsh also held the positions of president and chief operating officer of Gensia-Sicor, during which time he led the company’s commercial growth strategy, culminating in the eventual sale to Teva for $3.4 billion. Prior to Gensia, he spent 10 years in a global pharmaceutical company culminating in leading the U.S. and international business of a leading Japanese pharma company. Mr. Walsh has served on pharma boards as chairman, non-executive chairman and company director, as well as an executive advisor to private equity and venture capital firms. He currently serves on the board of Avista Pharma, which is backed by private-equity firm Ampersand Capital Partners.
“This is an advantageous time for CDMOs with the appropriate combination of leadership, technical capabilities, and scale to capitalize on the dramatically increasing demand within the industry. With it’s single-use, fully disposable manufacturing technologies and proven regulatory track record, Avid is well positioned to seize this opportunity,” said Mr. Walsh. “I am pleased to serve the company in its goal to capitalize on this dynamic and growing market opportunity.”
Avid Bioservices was established out of Peregrine’s internal biologics manufacturing and development capabilities and began formal operations in January 2002. The company has grown from an internal support operation to a full service CDMO that manufactures bulk drug substance for products that are approved and marketed in over 18 countries by leading biopharma companies. Avid was recently recognized as a leading CDMO by Life Science Leader as a recipient of multiple 2017 Contract Manufacturing Leadership Awards for Quality, Reliability, Capabilities, Expertise and Compatibility. The company has an outstanding regulatory inspection history and state-of-the-art cGMP manufacturing facilities.
About Peregrine Pharmaceuticals, Inc. Peregrine Pharmaceuticals, Inc. is a company transitioning from an R&D focused business to a pure play contract development and manufacturing organization (CDMO). Peregrine's in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com).
The company is pursuing to license or sell its proprietary R&D assets, including its lead immunotherapy candidate, bavituximab, which is currently being evaluated in clinical trials in combination with immune stimulating therapies for the treatment of various cancers. For more information, please visit www.peregrineinc.com.
About Avid Bioservices, Inc.
Avid Bioservices, a wholly owned subsidiary of Peregrine Pharmaceuticals, provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 20 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. For more information about Avid, please visit www.avidbio.com.
Important Additional Information Peregrine intends to file a proxy statement with the Securities and Exchange Commission (SEC) in connection with the solicitation of proxies for Peregrine's 2017 Annual Meeting (Proxy Statement) with an associated WHITE proxy card. Peregrine, its directors and certain of its executive officers will be participants in the solicitation of proxies from stockholders in respect of the 2017 Annual Meeting. Information regarding the names of Peregrine's directors and executive officers and their respective interests in Peregrine by security holdings or otherwise is set forth in the Annual Report on Form 10-K of Peregrine, for the fiscal year ended April 30, 2017, filed with the SEC on July 14, 2017, and Peregrine's proxy statement for the 2016 Annual Meeting, filed with the SEC on August 26, 2016. To the extent holdings of such participants in Peregrine's securities are not reported, or have changed since the amounts described, in the 2016 proxy statement, such changes have been reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC. Details concerning the nominees of Peregrine's Board of Directors for election at the 2017 Annual Meeting will be included in the Proxy Statement. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE COMPANY'S DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS THERETO, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and stockholders will be able to obtain a copy of the definitive proxy statement and other documents filed by Peregrine free of charge from the SEC's website, www.sec.gov. Peregrine's stockholders will also be able to obtain, without charge, a copy of the definitive Proxy Statement and other relevant filed documents by directing a request by mail to Peregrine, Corporate Secretary's Office, 14282 Franklin Avenue, Tustin, CA 92780, by calling Peregrine's proxy solicitor, MacKenzie Partners, Inc., toll-free at (800) 322-2885, or from Peregrine's website at www.Peregrine.com.
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Phosphatidylserine-Induced Conformational Modulation of Immune Cell Exhaustion-Associated Receptor TIM3.
Weber JK1, Zhou R2.
Author information
1
Abstract
In the face of chronic cancers and protracted viral infections, human immune cells are known to adopt an exhausted state in which their effector functions are lost. In recent years, a number of inhibitory receptors have been connected to the immune cell exhaustion phenotype; furthermore, ligands capable of activating these receptors have been discovered. The molecular mechanisms by which these ligands affect the exhausted states of immune cells, however, are largely unknown. Here, we present the results of molecular dynamics simulations of one potential exhaustion-associated system: the complex of human inhibitory receptor TIM3 (hTIM3) and its ligand phosphatidylserine (PSF). We find that PSF fundamentally alters the electrostatic environment within hTIM3's Ca2+ binding site, facilitating the formation of a salt bridge and freeing a tyrosine-containing strand. This liberated tyrosine then collapses into a nearby hydrophobic pocket, anchoring a modified conformational ensemble typified by a ß-strand rearrangement. The "electrostatic switching/hydrophobic anchoring" mechanism of conformational modulation reported here suggests a new type of process by which TIM3 activation might be achieved. This work also highlights strategies by which PSF-mediated conformational change could be controlled, either through administration of small molecules, execution of mutations, or modification of receptor phosphorylation states.
https://www.ncbi.nlm.nih.gov/pubmed/29051586
We know that already. Finito
Tell me, but don't write Ronin.
So burn the white card - greatest BS I have ever read.
09/07/2017
NCCN Announces First Patient Dosed in NCCN-Peregrine Pharmaceuticals Collaborative Study of Bavituximab
An NCCN ORP-funded study, examining effectiveness of bavituximab combination in patients with newly diagnosed glioblastomas, enrolled its first patient at Dana-Farber Cancer Institute in Boston, Massachusetts.
[FORT WASHINGTON, PA — September 7, 2017] Glioblastoma is the most common malignant primary brain tumor and is a uniformly fatal disease with five-year survival rates less than four percent despite aggressive treatment with surgery, radiation, and chemotherapy.1 Consequently, new therapies for this patient population are desperately needed.
The National Comprehensive Cancer Network® (NCCN®) today announced the dosing of the first patient in its Oncology Research Program (ORP)-funded study to investigate the effectiveness of bavituximab with radiation and temozolomide in patients with newly diagnosed glioblastomas.
The study, initiated by Elizabeth Gerstner, MD, Massachusetts General Hospital Cancer Center, is one of three studies funded through a collaboration between NCCN ORP and Peregrine Pharmaceuticals—this patient marks the first enrollment into an NCCN ORP-funded investigator-initiated bavituximab trial.
“NCCN ORP congratulates Dr. Gerstner and Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center for initiation of this study, as well as the other investigators who will soon embark on their research of bavituximab in patients with cancer,” said Susan Most, MBA, RN, Director, Clinical Operations, NCCN ORP. “The fact that Peregrine Pharmaceuticals has entrusted the NCCN ORP with these investigator-initiated studies is an honor, and we are happy that patients at our esteemed institutions will have access to this novel immunotherapy.”
The following researchers received funding through a grant from Peregrine Pharmaceuticals:
Elizabeth Gerstner, MD, Massachusetts General Hospital Cancer Center, “Phase II Clinical Trial of Bavituximab with Radiation and Temozolomide for Patients with Newly Diagnosed Glioblastoma”Jessica Frakes, MD, Moffitt Cancer Center, “A Phase I Trial of Sorafenib and Bavituximab Plus Stereotactic Body Radiation Therapy (SBRT) for First Line Treatment of Unresectable Hepatocellular Carcinoma”Ranee Mehra, MD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, “Phase II Study of Pembrolizumab and Bavituximab for Progressive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck”
Drs. Frakes and Mehra will begin enrolling patients in the coming months.
“We are hopeful that results from this trial, as well as from the two additional studies at NCCN Member Institutions, will continue to support our belief that bavituximab works to create a more immune active tumor microenvironment in which other therapies are able to have a greater anti-tumor effect,” said Joseph Shan, MPH, Vice President, Clinical and Regulatory Affairs of Peregrine. “We look forward to following this important study at the Massachusetts General Hospital Cancer Center, as well as the planned trials at the Moffitt Cancer Center and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.”
Bavituximab is an investigational immune-modulatory monoclonal antibody that targets phosphatidylserine (PS), a phospholipid that inhibits the ability of immune cells to recognize and fight tumors. Bavituximab is believed to reverse PS-mediated immunosuppression by blocking the engagement of PS with its receptors, as well as by sending an alternate immune activating signal.2 According to Peregrine, PS-targeting antibodies have been shown to shift the functions of immune cells in tumors, resulting in multiple signs of immune activation and anti-tumor immune responses. This mechanism may play an important role in allowing other cancer therapies to more effectively attack tumors by reversing the immunosuppression that limits the impact of those treatments.
Importantly, bavituximab has also demonstrated a favorable safety and tolerability profile across several clinical trials conducted to date, which may offer the compound a key advantage as the evolving cancer treatment landscape continues to shift to a combination therapy approach.
The awardees responded to a Request for Proposals issued by ORP to the NCCN Member Institutions and their affiliate hospitals. Submissions were peer reviewed by the NCCN Bavituximab Scientific Review Committee. The funded concepts were selected based on several criteria, including scientific merit, existing data, and the types of studies necessary to further evaluate the efficacy of bavituximab.
NCCN ORP draws on the expertise of investigators from NCCN Member Institutions and their affiliated hospitals to facilitate all phases of clinical research. The research is made possible by collaborations with pharmaceutical and biotechnology companies in order to advance therapeutic options for patients with cancer.
For more information about NCCN ORP, visit NCCN.org/ORP.
###
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.
The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.
Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients. Media, visit NCCN.org/news.
1CBTRUS (2008) Statistical report: primary brain tumors in the United States, 2000-2004. Central Brain Tumor Registry of the United States.
2Yin Y, Huang X, Lynn KD, Thorpe PE. Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation. Cancer immunology research 2013 Oct; 1(4): 256-268.
>View Article<
https://www.nccn.org/patients/about/member_institutions/news.aspx
MA 10.05 - Improved Outcome for Immune Checkpoint Inhibitors (ICI) in Patients Previously Treated with Bavituximab in the SUNRISE Trial (Now Available) (ID 8684)
11:30 - 11:35 | Presenting Author(s): Michael Boyer | Author(s): David R Spigel, P. Mainwaring, H. Lena, M. McCleod, G. Losonczy, R.E. Sanborn, R. Natale, M. Tang, J. Lai, N.L. Kallinteris, Joseph Shan, David E Gerber
:
Bavituximab targets exposed phosphatidylserine (PS) in the tumor microenvironment, resulting in repolarization of myeloid suppressor cells/M2 macrophages to M1, production of pro-inflammatory cytokines such as IFN? and IL-12, dendritic cell maturation, and tumor specific cytotoxic T-cell activation. SUNRISE was a Phase III trial of docetaxel with bavituximab (D+B) or placebo (D+P) in patients with treated Stage IIIb/IV non-squamous NSCLC. Recent correlative analyses from SUNRISE suggest bavituximab is more active in PD-L1 negative, immune cold tumors and thus may complement PD-1/PD-L1 ICI.
Method:
This subgroup analysis included all patients who received subsequent ICI after discontinuing SUNRISE study drug. We calculated overall survival (OS) both from randomization and start of subsequent ICI.
Result:
Ninety-three of 597 randomized patients (16%) received ICI as next line of therapy after SUNRISE assigned treatment. Baseline characteristics were balanced between the treatment groups and consistent with the ITT population. From randomization, mOS was not reached (95% confidence interval [CI], 15.2-NA) in D+B (N=46) and 12.6 months (95% CI, 10.4-17.8) in D+P (N=47) (hazard ratio [HR], 0.46; P=0.006) (Figure). From start of ICI, mOS was not reached (95% CI, 10.2-NA) in D+B and 6.2 months (95% CI, 3.9-8.7) in D+P (HR, 0.42; P=0.002). The mPFS was 6.0 months (95% CI, 3.5-6.5) in D+B and 4.4 months (95% CI, 2.6-6.3) in D+P (HR, 1.00; P=0.991). ORR was 20% vs. 13% (Odds ratio 0.6; P=0.41) for D+B and D+P, respectively. The safety profile was similar between groups and no immune related (IR) toxicities (colitis, pneumonitis, hypothyroidism) were reported.
Conclusion:
Within the limits of a subgroup analysis, a significant improvement in OS was observed for patients previously treated with D+B. Furthermore, bavituximab has not been associated with IR toxicities and might serve as a useful drug in combination with ICI for the treatment of immune cold tumors. Figure 1
Coordinates: 10/17/2017, 11:00 - 12:30, Room 303 + 304
https://library.iaslc.org/search-speaker?search_speaker=55135
Procoagulant microparticles derived from cancer cells have determinant role in the hypercoagulable state associated with cancer
Published online on: October 20, 2017
https://www.spandidos-publications.com/10.3892/ijo.2017.4170/abstract
Abstract
Hypercoagulablity is a common alteration of blood coagulation in cancer patients. However, the procoagulant activity of cancer cells is not sufficient to induce hypercoagulability. The present study was aimed to identify the mechanism with which hypercoagulabilty is produced in the presence of cancer cells. We focused on the analysis of the procoagulant elements carried by cancer cell-derived microparticles (CaCe-dMP) and we evaluated the impact of microparticles associated with the cancer cells from which they stem on thrombin generation. CaCe-dMP from the cancer cells were isolated from the conditioned medium and analyzed for tissue factor (TF) and procoagulant phospholipid expression. Thrombin generation of normal plasma was assessed by the Thrombinoscope (CAT®) in the presence or absence of pancreas adenocarcinoma cells (BXPC3) or breast cancer MCF7 cells supplemented with the respective CaCe-dMP. Both BXPC3 and MCF7 cells express abundant amounts of active TF. Phosphatidylserine was identified on the surface of CaCe-dMP, unlike the cancer cells themselves. The expression of TFa by the microparticles was significantly higher to that observed on the cancer cells. Culture of the cancer cells with their microparticles resulted in thrombin generation significantly higher as compared to the upper normal limit. In conclusion, cancer cells ‘enrich’ the microenvironment with procoagulant elements, especially procoagulant microparticles which express TF and procoagulant phospholipids. The association of cancer cells with procoagulant microparticles is necessary for a state of hypercoagulability, at the level of the tumoral microenvironment. The intensity of the hypercoagulability depends on the histological type of the cancer cells.
PLS delete if already posted! Published: October 09, 2015
Variation in human cancer cell external phosphatidylserine is regulated by flippase activity and intracellular calcium
Apoptotic Bodies Elicit Gas6-Mediated Migration of AXL-Expressing Tumor Cells
This is realy full with PS.
BWH - DANA-FARBER AND BRIGHAM AND WOMEN'S RESEARCHERS LAUD FDA APPROVAL OF CAR T-CELL THERAPY FOR NON-HODGKIN LYMPHOMA
PUBT
10/19/2017 4:10 PM
Oct 19, 2017
Dana-Farber and Brigham and Women's researchers laud FDA approval of CAR T-cell therapy for non-Hodgkin Lymphoma Following a successful clinical trial involving Dana-Farber Cancer Institute and Brigham and Women's Hospital, the first chimeric antigen receptor (CAR) T-cell therapy
(http://www.dana-farber.org/cellular-therapies-program/car-t-cell-therapy/) for adult cancers was approved by the Food and Drug Administration (FDA) today. Dana-Farber/Brigham and Women's Cancer Center, the only facility in the northeast to be part of the clinical trial, is one of a few locations certified to offer this new therapy nationwide.
The drug, known as Yescarta
(http://www.dana-farber.org/cellular-therapies-program/car-t-cell-therapy/yescarta-for-lymphoma/) (axicabtagene ciloleucel), was developed by Kite Pharma and can now be used to treat adults with refractory aggressive B cell non-Hodgkin lymphoma (NHL). The FDA ruling is based on the results of a clinical trial that showed the therapy to be safe and effective. On this nationwide trial, 101 patients received Yescarta and 82 percent of patients responded to the treatment, with 54 percent of patients having a complete response to therapy, according to results presented in June at the Lugano International Conference on Malignant Lymphoma. Thirty-six percent of patients remain in complete remission six months after treatment.
'Treating patients with CAR T-cells has been one of my most exciting professional experiences, and the FDA approval of this therapy offers hope and optimism to a subset of patients whose other treatments have failed them,' says Caron A. Jacobson, MD,
(https://physiciandirectory.brighamandwomens.org/details/362/caron-jacobson-cancer_-_medical_oncology-medical_oncology-boston) Medical Director of the Immune Effector Cell Therapy program at Dana-Farber/Brigham and Women's Cancer Center. 'It is extremely rewarding to be able to offer a new therapy to patients who had virtually no other options just 12 to 24 months ago.'
Over the past couple of years, Jacobson and her team have been testing Yescarta in a clinical trial. The patients on this study met the following qualifications:
Diagnosed with a highly refractory fast-growing B cell non-Hodgkin lymphoma -- called diffuse large B cell lymphoma, primary mediastinal B cell lymphoma, or transformed follicular lymphoma
Did not experience a positive response to past treatments or experienced disease progression following their last chemotherapy regimen
'This therapy requires just a one-time infusion for patients, and the results are evident within one month,' Jacobson said. 'It is our goal as clinicians to help patients and improve their quality of life. Seeing these patients return to work, their families, and their livelihoods so quickly is an important reminder of how far we have come. It is also inspiration for the work we still need to do.'
The approval follows the FDA's recent first-ever approval of CAR T-cell therapy for the treatment of some pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL) in August. (http://www.danafarberbostonchildrens.org/conditions/leukemia-and-lymphoma/acute-lymphoblastic-leukemia.aspx?_ga=2.5856755.1515634541.1508417244-157102980.1508417244) (http://www.danafarberbostonchildrens.org/news/dana-farber-boston-childrens-responds-to-fda-approval-of-car-t-cell-therapy.aspx?_ga=2.39017699.1515634541.1508417244-157102980.1508417244) CAR T-cell therapy, like all forms of cancer immunotherapy, seeks to sharpen and strengthen the immune system's inherent cancer-fighting powers. It involves giving patients modified versions of their own immune system T-cells
white blood cells that help protect the body from disease.
To convert normal T-cells into CAR T-cells, technicians first extract T-cells from a patient's blood and genetically engineer them in a lab to produce proteins on their surface called chimeric antigen receptors, or CARs. The CARs serve a dual purpose: to enable the T-cells to latch onto specific tumor cell proteins called antigens, and to signal the T-cells to kill those tumor cells. The newly minted CAR T-cells grow in a lab until they number in the hundreds of millions, and are then infused into the patient. If successful, the CAR T-cells will continue to reproduce in the patient's body, and serve as an effective fighting force against cancer cells.
The initial clinical trials of CAR T-cell therapy have involved pediatric and adult patients with blood-based cancers such as leukemia, lymphoma, and multiple myeloma. Based on the therapy's success so far, CAR T-cell therapy trials are now opening for certain types of solid tumors as well.
'The successful development of CAR T-cells as a therapy for cancer, on the heels of the success of immune checkpoint blockade drugs, is a testament to the progress we have made in understanding how our immune system is regulated and how cancer evades the immune system,' Jacobson said. 'It is a perfect example of how basic science research can fuel clinical progress. Now we need to take what we can from the clinic back to the laboratory to make this therapy even better.'
BWH - Brigham and Women's Hospital published this content on 19 October 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 19 October 2017 14:10:08 UTC.
Original document
http://www.brighamandwomens.org/about_bwh/publicaffairs/news/pressreleases/PressRelease.aspx?PageID=2859
Public permalink
http://www.publicnow.com/view/DDB91D5FD3D99127A2685633D88E8EBE6E4E8CBF
(C) Copyright 2017 - BWH - Brigham and Women's Hospital
OVERVIEW OF MOLECULAR TARGETED THERAPY IN CANCER
Published online 28th August, 2017
http://journalijcar.org/sites/default/files/issue-files/2652-A-2017.pdf
Peregrine Pharmaceuticals Announces Appointment of Mark R. Bamforth to Board of Directors of Peregrine and Avid Bioservices - GNW
19-Oct-2017 14:05
TUSTIN, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company focused on helping improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Mark R. Bamforth as an independent member of the board of directors of both Peregrine and Avid Bioservices, the company’s wholly-owned contract development and manufacturing organization (CDMO) subsidiary. Mr. Bamforth has 30 years of biologics leadership experience including founding two CDMOs, Brammer Bio, where he is currently the president and CEO, and Gallus BioPharmaceuticals, which was acquired by DPx Holdings B.V., the parent company of Patheon. Additionally, he served for more than 20 years in key roles at Genzyme Corporation, including 10 years as a corporate officer responsible for running global manufacturing.
“Mark is a great addition to the board of directors as we continue our transition to becoming a dedicated CDMO business. With his extensive experience in the CDMO space, both as an entrepreneur who has founded, grown, acquired and sold a successful CDMO company, as well as his experience as a key executive at Genzyme Corporation, he is ideally suited to help oversee the transition of the company into a leading CDMO,” said Steven W. King, president and chief executive officer of Peregrine. “Combined with the recent appointment of Dr. Roger Lias as president of Avid Bioservices and member of Peregrine’s board of directors, today’s appointment further underscores our commitment to reconstitute the board of directors with high quality CDMO industry experience. We look forward to providing further updates in the near future as we continue the process.”
Based in Cambridge, Massachusetts, Mr. Bamforth currently serves as the president and CEO of Brammer Bio, a cell and gene therapy CDMO that he founded in 2015 and merged with Florida Biologix, an established, 10-year old CDMO, in March 2016. In this role, he oversees a team of more than 300 employees providing services ranging from process development and early clinical supply services to production of Phase III clinical supplies and support for licensure of gene therapy products. Previously, he founded Gallus BioPharmaceuticals, a biologics CDMO that experienced rapid growth leading to its acquisition by DPx Holdings B.V., the parent company of Patheon, in 2014 for $257.2 million.
Prior to his founding of Brammer Bio and Gallus BioPharmaceuticals, Mr. Bamforth spent 22 years with Genzyme Corporation rising to the position of senior vice president of corporate operations and pharmaceuticals. In this role, he oversaw a multi-technology, global operations team comprised of more than 3,600 individuals at 13 internal sites and a network of 24 contract manufacturing organizations. This team was charged with supplying over 20 commercial products and multiple clinical products that spanned biologics, cell therapy, gene therapy, pharmaceuticals and biologic devices. While at Genzyme, Mr. Bamforth served as a member of the CEO’s operating committee, helping to guide corporate strategy acquisition, partnering and growth to over $4 billion in sales.
“We continue to see significant growth potential in the CDMO space, particularly for companies that understand the nuanced needs of biopharmaceutical companies and can offer creative and sophisticated development and manufacturing solutions. I believe that Avid Bioservices is well positioned to capitalize on these growth opportunities based on its state-of-the-art Myford manufacturing facility, as well as its established track record of commercial and clinical manufacturing and regulatory excellence,” stated Mr. Bamforth. “I am pleased to have the opportunity to join the boards of both Peregrine and Avid at this exciting time of transition for the companies and look forward to sharing my industry experience to contribute to the ongoing success of the CDMO business.”
Mr. Bamforth also serves on the boards of MassBio and the Wentworth Institute of Technology, and is a Saltire Foundation founding-trustee. He earned a bachelor of science in chemical engineering from Strathclyde University and an MBA from Henley Management College.
Avid Bioservices was established out of Peregrine’s internal biologics manufacturing and development capabilities and began formal operations in January 2002. The company has grown from an internal support operation to a full service CDMO that manufactures bulk drug substance for products that are approved and marketed in over 18 countries by leading biopharma companies. Avid was recently recognized as a leading CDMO by Life Science Leader as a recipient of multiple 2017 Contract Manufacturing Leadership Awards for Quality, Reliability, Capabilities, Expertise and Compatibility. The company has an outstanding regulatory inspection history and state-of-the-art cGMP manufacturing facilities. Mr. King has served as president of Avid since its formation in addition to his role as president and CEO of Peregrine Pharmaceuticals since 2003.
About Peregrine Pharmaceuticals, Inc. Peregrine Pharmaceuticals, Inc. is a company transitioning from an R&D focused business to a pure play contract development and manufacturing organization (CDMO). Peregrine's in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com).
The company is pursuing to license or sell its proprietary R&D assets, including its lead immunotherapy candidate, bavituximab, which is currently being evaluated in clinical trials in combination with immune stimulating therapies for the treatment of various cancers. For more information, please visit www.peregrineinc.com.
About Avid Bioservices, Inc.
Avid Bioservices, a wholly owned subsidiary of Peregrine Pharmaceuticals, provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 20 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. For more information about Avid, please visit www.avidbio.com.
Important Additional Information Peregrine intends to file a proxy statement with the Securities and Exchange Commission (SEC) in connection with the solicitation of proxies for Peregrine's 2017 Annual Meeting (Proxy Statement) with an associated WHITE proxy card. Peregrine, its directors and certain of its executive officers will be participants in the solicitation of proxies from stockholders in respect of the 2017 Annual Meeting. Information regarding the names of Peregrine's directors and executive officers and their respective interests in Peregrine by security holdings or otherwise is set forth in the Annual Report on Form 10-K of Peregrine, for the fiscal year ended April 30, 2017, filed with the SEC on July 14, 2017, and Peregrine's proxy statement for the 2016 Annual Meeting, filed with the SEC on August 26, 2016. To the extent holdings of such participants in Peregrine's securities are not reported, or have changed since the amounts described, in the 2016 proxy statement, such changes have been reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC. Details concerning the nominees of Peregrine's Board of Directors for election at the 2017 Annual Meeting will be included in the Proxy Statement. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE COMPANY'S DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS THERETO, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and stockholders will be able to obtain a copy of the definitive proxy statement and other documents filed by Peregrine free of charge from the SEC's website, www.sec.gov. Peregrine's stockholders will also be able to obtain, without charge, a copy of the definitive Proxy Statement and other relevant filed documents by directing a request by mail to Peregrine, Corporate Secretary's Office, 14282 Franklin Avenue, Tustin, CA 92780, by calling Peregrine's proxy solicitor, MacKenzie Partners, Inc., toll-free at (800) 322-2885, or from Peregrine's website at www.Peregrine.com.
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
Joel Shilyansky, MD
https://medicine.uiowa.edu/surgery/profile/joel-shilyansky
Molecular Mechanisms Involved in the Immune Control of the Malignant Disease Process
Abstract
** Citi is the second brokerage, after Credit Suisse (Full Story), to downgrade Roche ROG.S to "neutral" from "buy" this week
** It says Roche's rate of progress in the field of immuno-oncology has underperformed broker's expectations set out in 2015
** "We are concerned that the near-term impact of biosimilars in EU will prove more negative to Roche's P&L than envisaged by consensus", broker adds
** Removes Roche from the Citi Focus List and prefers "buy"-rated AstraZeneca Plc AZN.L and Bayer BAYGn.DE in Europe
** Q3 sales (due Oct. 19) likely to show first signs of biosimilars impact, according to analysts (Full Story)
First time for me
Preliminary Study on the Role of Protein Kinase C in Cd47-Mediated
Phosphatidylserine Exposure Pathway By Bric 126 In Jurkat T Cells
https://www.google.at/url?sa=t&source=web&rct=j&url=http://www.scholarsresearchlibrary.com/articles/preliminary-study-on-the-role-of-protein-kinase-c-in-cd47mediated-phosphatidylserine-exposure-pathway-by-bric-126-in-jur.pdf&ved=0ahUKEwj8jcTRsfjWAhXmCJoKHVtNBMc4PBAWCDAwBg&usg=AOvVaw3wiMNWfV6slfcgflR2tgb7
I don't know.......
Detection of phosphatidylserine in the plasma membrane of single apoptotic cells using electrochemiluminescence†
http://pubs.rsc.org/en/content/articlehtml/2017/RA/C6RA28031E